118 related articles for article (PubMed ID: 18281249)
21. CHEK2 1100delC, IVS2+1G>A and I157T mutations are not present in colorectal cancer cases from Turkish population.
Bayram S; Topaktaş M; Akkız H; Bekar A; Akgöllü E
Cancer Epidemiol; 2012 Oct; 36(5):453-7. PubMed ID: 22521562
[TBL] [Abstract][Full Text] [Related]
22. Increased risk of breast cancer associated with CHEK2*1100delC.
Weischer M; Bojesen SE; Tybjaerg-Hansen A; Axelsson CK; Nordestgaard BG
J Clin Oncol; 2007 Jan; 25(1):57-63. PubMed ID: 16880452
[TBL] [Abstract][Full Text] [Related]
23. Epistatic relationship between the cancer susceptibility genes CHEK2 and p27.
Cybulski C; Gliniewicz B; Sikorski A; Kładny J; Huzarski T; Gronwald J; Byrski T; Debniak T; Gorski B; Jakubowska A; Wokolorczyk D; Narod SA; Lubiñski J
Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):572-6. PubMed ID: 17372254
[TBL] [Abstract][Full Text] [Related]
24. Sequence variants of NAT1 and NAT2 and other xenometabolic genes and risk of lung and aerodigestive tract cancers in Central Europe.
McKay JD; Hashibe M; Hung RJ; Wakefield J; Gaborieau V; Szeszenia-Dabrowska N; Zaridze D; Lissowska J; Rudnai P; Fabianova E; Mates D; Foretova L; Janout V; Bencko V; Chabrier A; Hall J; Boffetta P; Canzian F; Brennan P
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):141-7. PubMed ID: 18199719
[TBL] [Abstract][Full Text] [Related]
25. CHEK2 1100delC is a susceptibility allele for HNPCC-related colorectal cancer.
Wasielewski M; Vasen H; Wijnen J; Hooning M; Dooijes D; Tops C; Klijn JG; Meijers-Heijboer H; Schutte M
Clin Cancer Res; 2008 Aug; 14(15):4989-94. PubMed ID: 18676774
[TBL] [Abstract][Full Text] [Related]
26. Point: myeloperoxidase -463G --> a polymorphism and lung cancer risk.
Feyler A; Voho A; Bouchardy C; Kuokkanen K; Dayer P; Hirvonen A; Benhamou S
Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1550-4. PubMed ID: 12496042
[TBL] [Abstract][Full Text] [Related]
27. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma.
Gajecka M; Rydzanicz M; Jaskula-Sztul R; Kujawski M; Szyfter W; Szyfter K
Mutat Res; 2005 Jul; 574(1-2):112-23. PubMed ID: 15914211
[TBL] [Abstract][Full Text] [Related]
28. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
Falchetti M; Lupi R; Rizzolo P; Ceccarelli K; Zanna I; Calò V; Tommasi S; Masala G; Paradiso A; Gulino A; Giannini G; Russo A; Palli D; Ottini L
Breast Cancer Res Treat; 2008 Jul; 110(1):161-7. PubMed ID: 17661168
[TBL] [Abstract][Full Text] [Related]
29. Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer.
Park JY; Lee SY; Jeon HS; Bae NC; Chae SC; Joo S; Kim CH; Park JH; Kam S; Kim IS; Jung TH
Cancer Epidemiol Biomarkers Prev; 2002 Jan; 11(1):23-7. PubMed ID: 11815397
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapy.
Meyer A; Dörk T; Sohn C; Karstens JH; Bremer M
Radiother Oncol; 2007 Mar; 82(3):349-53. PubMed ID: 17250914
[TBL] [Abstract][Full Text] [Related]
31. p53 mutations in head and neck cancer: new data and evaluation of mutational spectra.
Olshan AF; Weissler MC; Pei H; Conway K
Cancer Epidemiol Biomarkers Prev; 1997 Jul; 6(7):499-504. PubMed ID: 9232336
[TBL] [Abstract][Full Text] [Related]
32. The associations of sequence variants in DNA-repair and cell-cycle genes with cancer risk: genotype-phenotype correlations.
Hall J; Marcel V; Bolin C; Fernet M; Tartier L; Vaslin L; Hainaut P
Biochem Soc Trans; 2009 Jun; 37(Pt 3):527-33. PubMed ID: 19442246
[TBL] [Abstract][Full Text] [Related]
33. CHEK2 1100delC and male breast cancer in the Netherlands.
Wasielewski M; den Bakker MA; van den Ouweland A; Meijer-van Gelder ME; Portengen H; Klijn JG; Meijers-Heijboer H; Foekens JA; Schutte M
Breast Cancer Res Treat; 2009 Jul; 116(2):397-400. PubMed ID: 18759107
[TBL] [Abstract][Full Text] [Related]
34. Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer.
Złowocka E; Cybulski C; Górski B; Debniak T; Słojewski M; Wokołorczyk D; Serrano-Fernández P; Matyjasik J; van de Wetering T; Sikorski A; Scott RJ; Lubiński J
Int J Cancer; 2008 Feb; 122(3):583-6. PubMed ID: 17918154
[TBL] [Abstract][Full Text] [Related]
35. CHEK2 I157T and colorectal cancer in Bulgaria.
Konstantinova D; Kadiyska T; Sokolova V; Kaneva R; Mirchev M; Savov A; Aleksandrova A; Nedin D; Kostadinov E; Damyanov D; Kremensky I; Mitev V
J BUON; 2010; 15(2):314-7. PubMed ID: 20658728
[TBL] [Abstract][Full Text] [Related]
36. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
[TBL] [Abstract][Full Text] [Related]
37. Somatic alterations of the serine/threonine kinase LKB1 gene in squamous cell (SCC) and large cell (LCC) lung carcinoma.
Strazisar M; Mlakar V; Rott T; Glavac D
Cancer Invest; 2009 May; 27(4):407-16. PubMed ID: 19229701
[TBL] [Abstract][Full Text] [Related]
38. Characterization of CHEK2 mutations in prostate cancer.
Wu X; Dong X; Liu W; Chen J
Hum Mutat; 2006 Aug; 27(8):742-7. PubMed ID: 16835864
[TBL] [Abstract][Full Text] [Related]
39. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant--463A of the myeloperoxidase gene.
Cascorbi I; Henning S; Brockmöller J; Gephart J; Meisel C; Müller JM; Loddenkemper R; Roots I
Cancer Res; 2000 Feb; 60(3):644-9. PubMed ID: 10676648
[TBL] [Abstract][Full Text] [Related]
40. CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden.
Wagenius M; Borg A; Johansson L; Giwercman A; Bratt O
Scand J Urol Nephrol; 2006; 40(1):23-5. PubMed ID: 16452051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
